Type 1 diabetes, once known as juvenile diabetes, is defined as an autoimmune or idiopathic
destruction of β cells that causes severe insulin deficiency in contrast to type 2
diabetes, which is characterised by insulin resistance. Historically, type 1 diabetes
has been considered as a disease that primarily affects children and adolescents (aged
10–19 years) and, consequently, diagnosis, clinical care, and advocacy has largely
been focused on younger populations. However, findings from recent epidemiological
studies and the development of the type 1 diabetes index—a data simulation tool that
estimates the number of type 1 diabetes cases for all ages across countries—have shown
that the majority of incidence and prevalent cases of type 1 diabetes are in adults.
It is estimated that up to 40% of adults older than 30 years with type 1 diabetes
might have been misdiagnosed with type 2 diabetes. Considering that the life expectancy
of people with type 1 diabetes is reduced by up to 8 years when compared with the
general population, in contrast to 3 years for type 2 diabetes, a paradigm shift towards
a greater awareness of type 1 diabetes in adults in the clinical and research field
is needed. The global agenda, which is overwhelmingly focused on the prevention and
treatment of type 2 diabetes in adults, must be expanded to include type 1 diabetes,
which has its own challenges, mainly its diagnosis and subsequent appropriate treatment.
One of the fundamental challenges with the misdiagnosis of type 1 diabetes in adults
is the assumption that an adult with diabetes would have type 2 diabetes by default.
Another important factor contributing to misdiagnosis is that some adults with type
1 diabetes might not need insulin at the time of diagnosis (eg, patients with latent
autoimmune diabetes of adults), so their clinical disease might be masked as type
2 diabetes. Additionally, some risk factors for type 2 diabetes, such as obesity and
metabolic syndrome, are now much more common in the general population and cannot
be used to rule out a diagnosis of type 1 diabetes. Furthermore, quite often there
is poor accessibility to perform diagnostic tests, such as islet autoantibodies and
C-peptide measurement, that can distinguish type 1 from type 2 diabetes. However,
it is also important to acknowledge that the diagnostic algorithm for type 1 diabetes
is not as straightforward as for type 2 diabetes, which makes classification even
more difficult.
The adverse consequence of type 1 diabetes misdiagnosis is that it affects management
of the disease, which is different from type 2 diabetes, and the mismanagement negatively
affects the quality of life and survival of patients. The cornerstone treatment of
type 1 diabetes is intensive insulin therapy to prevent long-term complications, but
treatment strategies should also aim to minimise the psychosocial burden of the disease.
Fortunately, the development of new technologies promises to achieve this. Continuous
glucose monitoring (CGM), consisting of a subcutaneous sensor that continuously measures
glucose levels in interstitial fluid, reduces the number of finger pricks needed,
and avoids fluctuations in blood glucose levels thus providing a more personalised
care. Regarding insulin delivery, different insulin pumps and hybrid closed-loop systems
(also called artificial pancreas or automated insulin delivery) have been shown to
be safe and to improve glycaemic control in youths and adults with type 1 diabetes,
but require continuous user input. Additional sophisticated technologies are currently
being evaluated, such as the bionic pancreas, a fully automated closed-loop system,
which is initialised only on the basis of bodyweight without requiring continuous
input from the user. Although these advanced technologies are encouraging, their high
cost makes them unaffordable for the majority of people with type 1 diabetes.
It is time for the medical, research, and public health community to turn their attention
to type 1 diabetes in adults and to develop strategies to tackle the challenges that
this disease poses. Health-care professionals should start including type 1 diabetes
in their diagnostic arsenal when treating adults, but also the scientific and medical
community must push for the development of an effective diagnostic decision tree with
specific biomarkers to help correctly classify the type of diabetes. Adults with type
1 diabetes need to be better represented in research and deserve equitable access
to novel technologies. A crucial first step is to raise awareness that type 1 diabetes
is far more common in adults than previously thought.